Merit Financial Group LLC Has $5.04 Million Stock Holdings in Pfizer Inc. $PFE

Merit Financial Group LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 30.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 207,849 shares of the biopharmaceutical company’s stock after purchasing an additional 48,978 shares during the period. Merit Financial Group LLC’s holdings in Pfizer were worth $5,038,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth approximately $28,000. Horizon Financial Services LLC bought a new position in shares of Pfizer in the 1st quarter worth $35,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer in the 1st quarter valued at $35,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of several research reports. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Morgan Stanley lifted their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.41.

Pfizer Price Performance

Pfizer stock opened at $26.45 on Tuesday. The stock has a market cap of $150.38 billion, a P/E ratio of 14.07, a P/E/G ratio of 0.88 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company’s 50 day moving average price is $24.72 and its two-hundred day moving average price is $24.12. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.